Stocks to Buy

Identifying winning stocks requires more than scanning headlines. InvestorPlace analysts focus on long-term themes, market timing, and structural shifts shaping where capital is flowing next, highlighting stocks positioned to benefit from those trends.

4 Commercial Banking Stocks to Buy Now

By Portfolio Grader
Four Commercial Banking stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an "A" ("strong buy") or "B" overall ("buy").

3 ‘Real-Deal’ Cloud Companies to Buy

By Tom Taulli, InvestorPlace Contributor
Numerous tech names say they're "cloud operators," but some companies are much more likely to profit than others off this booming technology.

5 Stocks With Strong Earnings Growth — XXIA GA MLNX MOV CAMP

By Portfolio Grader
This week, these five stocks have the best ratings in Earnings Growth, one of the eight Fundamental Categories on Portfolio Grader.

5 Stocks With Superb Cash Flow — XIN ZX ZA CRAY RCII

By Portfolio Grader
This week, these five stocks have the best ratings in Cash Flow, one of the eight Fundamental Categories on Portfolio Grader.

Buffett Said ‘Bye’ to This, But I Say ‘Buy!’

By Bryan Perry
Warren Buffett may have ended his bet on municipal bonds, but that doesn't mean you should. Their bad rap could overshadow a good investment.

5 Health Care Provider Stocks to Buy Now

By Portfolio Grader
The grades of five Health Care Provider stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an "A" ("strong buy") or "B" overall ("buy") rating.

Bet on Biotech With ViroPharma

By Jon Markman, Editor, Trader's Advantage and CounterPoint Options
Biotech stocks are speculative picks. But if you're willing to take a risk, ViroPharma is the way to go.

Wal-Mart Looks Like a Winner

By Charles Sizemore, Chief Investment Strategist, The Freeport Society
No matter what happens with the uncertain economy down the line, Wal-Mart looks like a promising pick.

Buy These 6 Stocks When the Inevitable Sell-Off Hits

By Jeff Reeves
There's plenty to suggest a short-term sell-off is on its way. So, set your sights on some stock bargains to scoop up when it happens. Here are six to watch.

Top 6 Stocks to Buy for September

By Sam Collins, InvestorPlace Chief Technical Analyst
These six picks should provide for a higher-than-average degree of stability and return despite the international risks. See this month's buy list.

5 Best Sectors to Watch This Week

By Portfolio Grader
This week, Leisure Goods, Water Utilities, Household Products, Infrastructure, and Tobacco are the best sectors on the Portfolio Grader database.

5 Stocks With Great Operating Margin Growth — UFCS WAL MLNX CRAY CLUB

By Portfolio Grader
 

Believe in IAC’s Bet on About.com

By Tom Taulli, InvestorPlace Contributor
Expect Internet stock IAC/InterActiveCorp to do good things with its $300 million purchase of About.com from The New York Times Co.

5 Stocks With Strong Sales Growth — CRIS DRRX AGX MCC FHCO

By Portfolio Grader
This week, these five stocks have the best ratings in Sales Growth, one of the eight Fundamental Categories on Portfolio Grader.

4 Medical Devices Stocks to Buy Now

By Portfolio Grader
The grades of four Medical Devices stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy").

3 Media Stocks to Buy Now

By Portfolio Grader
This week, three Media stocks are improving their overall rating on Portfolio Grader. Each of these rates an "A" ("strong buy") or "B" overall ("buy").

4 Capital Markets Stocks to Buy Now

By Portfolio Grader
This week, four Capital Markets stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy").

5 Back-to-School All-Star Stocks

By Traders Reserve
Back to school time means shopping and that bodes well for these 5 back to school stocks to consider for the portfolio.

Gilead Poised to Go From Good to Great?

By James Brumley, InvestorPlace Feature Writer
Gilead faces a pivotal FDA decision on its HIV "quad" pill Monday. Even if it's not much better than what's available, approval would be good news for investors.
Load More Articles